Meeting
2012 Breast Cancer Symposium
Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC).
Authors
Denise Yardley
Sarah Cannon Research Institute/Tennessee Oncology
Denise Yardley , Debu Tripathy , Adam Brufsky , Hope Rugo , Peter Kaufman , Musa Mayer , Shibao Feng , Oyewale Abidoye , Marianne Ulcickas Yood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Survivorship and Health Policy,Systemic Therapy,Local/Regional Therapy
Sub Track
HER2+
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 133)
DOI
10.1200/jco.2012.30.27_suppl.133
Abstract #
133
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese
Poster
2023 ASCO Annual Meeting
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.
First Author: Charlotte Andrieu
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada
Poster
2014 ASCO Annual Meeting
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.
First Author: Diep Ho